Expand all sections

Zolbetuximab

Vyloy

Extended indication Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for
Therapeutic value Possibly no place in the treatment regimen
Registration phase Registered

Product

Active substance Zolbetuximab
Domain Oncology
Reason of inclusion New medicine (specialité)
Main indication Stomach cancer
Extended indication Vyloy, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with locally advanced unresectable or metastatic HER2‑negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma whose tumours are Claudin (CLDN) 18.2 positive
Proprietary name Vyloy
Manufacturer Astellas
Portfolio holder Astellas
Mechanism of action Immunostimulation
Route of administration Intravenous
Therapeutical formulation Intravenous drip
Budgetting framework Intermural (MSZ)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
ATMP No
Submission date June 2023
Expected Registration September 2024
Orphan drug Yes
Registration phase Registered
Additional remarks Positieve CHMP opinie juli 2024 en EC decision in september 2024

Therapeutic value

Current treatment options Huidige behandelopties zijn CAPOX / mFOLFOX.
Therapeutic value Possibly no place in the treatment regimen
Substantiation First in class, nieuwe target therapie. Er was een reductie van overlijden ten opzichte van placebo (HR 0,75, 95% CI 0·60–0·94; p=0·0053). De paskwil-criteria zijn niet gehaald.
Frequency of administration 1 times every 3 weeks
Dosage per administration 600-800 mg/m2
References NCT03653507

Expected patient volume per year

Patient volume

75 - 100

Market share is generally not included unless otherwise stated.
References (1) NKR; (record avelumab); (2) A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study - PMC (nih.gov)
Additional remarks (1) Het aantal patiënten dat eerste lijn systemische therapie heeft gehad voor onresectable locally advanced of gemetastaseerd voor adenocarcinoom van de maag of gastro-oesofageale overgang lag tussen 2015 en 2017 tussen de 330 en 350 patiënten per jaar. Vaak worden geneesmiddelen die initieel zijn goedgekeurd voor deze groep ook ingezet voor patiënten met adenocarcinoom van de slokdarm. Dit zou betekenen dat er in totaal ongeveer 260 tot 290 patiënten per jaar in aanmerking komen voor deze behandeling. (2) Volgens de aanname in MONO studie heeft 31% van de patiënten voldoende expressie van CLAUDINE 18.2 voor behandeling. Er zullen dan 75 tot 100 patiënten in aanmerking komen.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension Yes
Indication extensions Pancreas
Additional remarks 2026

Other information

There is currently no futher information available.